MedTech investors are facing an increasingly difficult choice. On one side is Abbott Laboratories (NYSE:ABT), a diversified healthcare company steadily expanding across diagnostics, medical devices, and nutrition. On the other hand is Intuitive Surgical (NASDAQ:ISRG), the undisputed leader in robotic surgery, whose premium valuation reflects expectations for years of continued growth.

Both companies delivered strong quarterly results, yet the market reacted very differently. Abbott (NYSE:ABT) raised its annual profit outlook after another solid quarter, while Intuitive Surgical (NASDAQ:ISRG) beat both revenue and earnings expectations but saw its shares decline as investors focused on slowing domestic procedure growth.

The divergence raises an important question: which MedTech stock offers the better long-term upside for investors?

Growth Drivers

Abbott’s (NYSE:ABT) second-quarter results reinforced one of its greatest competitive strengths: diversification. Rather than relying on a single business to drive growth, the company delivered encouraging performance across multiple operating segments, reducing its dependence on any one end market.

Diagnostics was one of the quarter’s standout performers. Revenue increased 42% year over year to $3.09 billion, exceeding analysts’ expectations of $3.02 billion. The company’s cancer diagnostics business, strengthened through the Exact Sciences acquisition, continues to benefit from growth in both new and repeat users of the Cologuard colorectal cancer screening test. The results suggest that diagnostics is becoming an increasingly meaningful contributor alongside Abbott’s (NYSE:ABT) established medical device franchise rather than simply a complementary business.

Intuitive Surgical’s (NASDAQ:ISRG) investment case rests on a very different foundation. Rather than diversification, its competitive advantage comes from the strength of its robotic surgery ecosystem and the recurring revenue it generates. Approximately 85% of the company’s second-quarter revenue came from recurring sources tied to its growing installed base of da Vinci surgical systems. That recurring revenue model provides meaningful earnings visibility because every new system placement creates an ongoing stream of revenue long after the initial sale.

The installed base continued expanding during the quarter. Intuitive (NASDAQ:ISRG) placed 468 da Vinci systems, representing 18% year-over-year growth, while adoption of the company’s newest da Vinci 5 platform continued to accelerate. Continued placements are particularly important because they expand the installed base that supports future recurring revenue.

What Could Slow Future Growth?

Abbott’s (NYSE:ABT) outlook remains encouraging, but much of its expected acceleration still depends on execution during the second half of the year. Although management raised its adjusted EPS outlook, it reaffirmed rather than increased its comparable sales growth guidance of 6.5% to 7.5%, suggesting a measured approach toward revenue expectations despite a strong quarter. Investors will likely be watching whether upcoming pipeline launches and improving momentum across several business segments translate into the stronger sales and earnings growth management expects.

For Intuitive Surgical (NASDAQ:ISRG), the market’s biggest concern is not profitability but growth. Despite delivering another earnings beat, management maintained its expectation for full-year da Vinci procedure growth of 13.5% to 15.5%, with results expected to trend toward the midpoint of that range. The market’s negative reaction suggests investors were hoping for stronger procedure guidance given the company’s premium valuation.

What Does Valuation and Institutional Positioning Say?

Valuation tells an interesting story. Intuitive Surgical (NASDAQ:ISRG)  trades at a forward P/E of 35.10, representing an 81.88% premium to the sector, while Abbott (NYSE:ABT) trades at a forward P/E of 19.54, or just a 1.27% premium. The gap suggests investors continue to place a significantly higher value on Intuitive’s long-term growth prospects and recurring revenue model, whereas Abbott (NYSE:ABT) is priced more like a diversified healthcare compounder.

Wall Street appears to share that optimism. The median analyst price target implies 22.78% upside for Intuitive Surgical (NASDAQ:ISRG), compared with 9.56% for Abbott (NYSE:ABT), indicating that analysts continue to see greater appreciation potential in Intuitive despite its richer valuation.

Institutional positioning offers additional context. According to Insider Monkey’s database of 1,022 hedge funds, Abbott’s (NYSE:ABT) hedge fund ownership increased modestly from 71 funds at the end of the fourth quarter of 2025 to 73 funds in the first quarter of 2026. Intuitive Surgical (NASDAQ:ISRG), meanwhile, saw hedge fund ownership decline from 109 funds to 103 over the same period. While the changes are relatively small, institutional positioning was somewhat more constructive toward Abbott (NYSE:ABT) during the quarter.

Which Stock Looks Better Positioned?

Abbott (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) represent two very different ways to invest in MedTech. Abbott offers the stability of a diversified healthcare business, with multiple growth engines helping reduce reliance on any single product category or procedure trend. Intuitive Surgical (NASDAQ:ISRG), meanwhile, remains one of the industry’s highest-quality growth companies, supported by a recurring revenue model, expanding installed base, and strong operating margins.

The trade-off lies in expectations. Abbott’s (NYSE:ABT) diversified portfolio provides greater resilience if one business temporarily slows, while Intuitive’s premium growth profile leaves investors more sensitive to changes in procedure growth or adoption trends. As a result, Abbott (NYSE:ABT) may appeal more to investors seeking consistent earnings growth, whereas Intuitive Surgical (NASDAQ:ISRG) could offer greater long-term upside if it continues expanding its robotic surgery ecosystem and sustaining strong recurring revenue growth.

Ultimately, the better investment depends on what investors are looking for, whether they want the predictability of a diversified healthcare company or the upside of a premium growth company. Those prioritizing consistency and a balanced growth profile may find Abbott (NYSE:ABT) more attractive. Investors willing to accept higher expectations in exchange for greater long-term growth potential may prefer Intuitive Surgical (NASDAQ:ISRG).

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

Disclosure: None. This article is originally published at Insider Monkey.